Affiliation:
1. Centre for Infectious Diseases and Microbiology, University of Sydney at Westmead, and Department of Infectious Diseases, ICPMR Building, Westmead Hospital, Westmead, NSW 2145
2. Women's and Children's Hospital, North Adelaide, South Australia 5006, Australia
3. Centre for Clinical Research Excellence in Infections & Bioethics in Haematological Malignancies, University of Sydney, Sydney, NSW 2006
Abstract
ABSTRACT
The alkyl phosphocholine drug miltefosine is structurally similar to natural substrates of the fungal virulence determinant phospholipase B1 (PLB1), which is a potential drug target. We determined the MICs of miltefosine against key fungal pathogens, correlated antifungal activity with inhibition of the PLB1 activities (PLB, lysophospholipase [LPL], and lysophospholipase-transacylase [LPTA]), and investigated its efficacy in a mouse model of disseminated cryptococcosis. Miltefosine inhibited secreted cryptococcal LPTA activity by 35% at the subhemolytic concentration of 25 μM (10.2 μg/ml) and was inactive against mammalian pancreatic phospholipase A2 (PLA
2
). At 250 μM, cytosolic PLB, LPL, and LPTA activities were inhibited by 25%, 51%, and 77%, respectively. The MICs at which 90% of isolates were inhibited (MIC
90
s) against
Candida albicans
,
Candida glabrata
,
Candida krusei
,
Cryptococcus neoformans
,
Cryptococcus gattii
,
Aspergillus fumigatus
,
Fusarium solani
,
Scedosporium prolificans
, and
Scedosporium apiospermum
were 2 to 4 μg/ml. The MICs of miltefosine against
Candida tropicalis
(
n
= 8) were 2 to 4 μg/ml, those against
Aspergillus terreus
and
Candida parapsilosis
were 8 μg/ml (MIC
90
), and those against
Aspergillus flavus
(
n
= 8) were 2 to 16 μg/ml. Miltefosine was fungicidal for
C. neoformans
, with rates of killing of 2 log units within 4 h at 7.0 μM (2.8 μg/ml). Miltefosine given orally to mice on days 1 to 5 after intravenous infection with
C. neoformans
delayed the development of illness and mortality and significantly reduced the brain cryptococcal burden. We conclude that miltefosine has broad-spectrum antifungal activity and is active in vivo in a mouse model of disseminated cryptococcosis. The relatively small inhibitory effect on PLB1 enzyme activities at concentrations exceeding the MIC by 2 to 20 times suggests that PLB1 inhibition is not the only mechanism of the antifungal effect.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
136 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献